Efficacies of osaterone and delmadinone in the treatment of benign prostatic hyperplasia in dogs

  title={Efficacies of osaterone and delmadinone in the treatment of benign prostatic hyperplasia in dogs},
  author={M Albouy and Annaele Sanquer and Laurence Maynard and H M Eun},
  journal={Veterinary Record},
  pages={179 - 183}
A multicentre randomised clinical trial was performed to compare the therapeutic potential of osaterone acetate with that of delmadinone acetate in the treatment of benign prostatic hyperplasia in dogs. The osaterone was administered orally at 0·25 mg/kg bodyweight once a day for seven days to 73 dogs. The delmadinone was administered by a single intramuscular or subcutaneous injection at 3 mg/kg bodyweight to 69 dogs. During the 180-day trial, the dogs were monitored five times for their… Expand
The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia.
In conclusion, OSA quickly reduced clinical signs and volume of the prostate glands in dogs with BPH. Expand
Comparison of Clinical Effectiveness of Deslorelin Acetate and Osaterone Acetate in Dogs with Benign Prostatic Hyperplasia
The clinical trial proved both drugs to be safe and effective in reducing BPH-related symptoms in dogs, and the noted adverse effects were only mild—mostly weight gain. Expand
Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs.
Finasteride treatment reduces simultaneously the volume, local vascularization and blood flow of the prostate, thus, being considered an effective and additional choice of therapy for BPH. Expand
Pharmacological treatment for common prostatic conditions in dogs - benign prostatic hyperplasia and prostatitis: an update.
The efficiency of GnRH antagonists used for the treatment of prostatic diseases, such as neoplasia and BPH, in humans has been recently investigated in dogs. Expand
Canine Prostate Disease.
  • B. Christensen
  • Medicine
  • The Veterinary clinics of North America. Small animal practice
  • 2018
Treatment recommendations include reducing antibiotic exposure to 4 weeks for bacterial infections and use of nonsteroidal antiinflammatory drugs for neoplastic disease and Castration is compared with medical treatment options. Expand
Update on medical management of benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is the most common prostatic abnormality of entire male dogs. It has been estimated to occur (either grossly or microscopically) in over 80% of entire males overExpand
B-Mode and Doppler Ultrasonographic Findings of Prostate Gland and Testes in Dogs Receiving Deslorelin Acetate or Osaterone Acetate
The present study proved the usefulness of B-mode and color Doppler US imaging techniques for diagnosis and progress assessment of dogs suffering from BPH. Expand
The problem stud dog.
  • C. Lopate
  • Medicine
  • The Veterinary clinics of North America. Small animal practice
  • 2012
The diagnostic work-up, differentials, and treatments for infertility in stud dogs, including infertility in dogs with high sperm count, are reviewed. Expand


Regression of prostatic hypertrophy by osaterone acetate in dogs.
It was shown that administration of osaterone acetate at 0.2 mg/kg or higher, sharply regressed prostatic hypertrophy during the early stage, and this agent may be clinically applicable as a therapeutic agent for benign prostatichypertrophy. Expand
Effects of delmadinone acetate on pituitary-adrenal function, glucose tolerance and growth hormone in male dogs.
Neither glucose intolerance nor hypersomatotropism seems likely in male dogs given delmadinone acetate at the recommended dose rate, but the potential for excessive growth hormone secretion in treated bitches remains undetermined. Expand
The effects of chlormadinone acetate (CMA), antiandrogen, on the pituitary, testis, prostate and adrenal gland of the dog with spontaneous benign prostatic hyperplasia.
It is concluded that CMA (0.03 and 0.1 mg/kg) causes regression of spontaneous canine BPH without any histopathological effects on the testes, adrenal glands or pituitary LH- and ACTH-cells. Expand
Effect of osaterone acetate administration on prostatic regression rate, peripheral blood hormone levels and semen quality in dogs with benign prostatic hypertrophy.
The effects of osaterone acetate, which is an anti-androgen agent being developed as a therapeutic drug for benign prostatic hypertrophy (BPH) in dogs, on the degree of prostatic regression and semen qualities were investigated and suggested that OSA is clinically applicable and inhibits prostatichypertrophy during the early phase. Expand
Treatment options for benign prostatic hyperplasia
  • T. Wilt
  • Medicine
  • BMJ : British Medical Journal
  • 2002
Treatment options for benign prostatic hyperplasia include watchful waiting, phytotherapies, prescription medications, surgical procedures, and minimally invasive techniques, and reliable information about efficacy and safety of various treatments is provided. Expand
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
The role of 5alpha-reductase inhibitors in the treatment of BPH has been firmly established with an adverse events profile that is suitable for long-term use. Expand
Inhibitory Influence of a New Steroidal Anti‐androgen, TZP‐4238, on Prostatic Hyperplasia in the Beagle Dog
It is concluded that TZP‐4238 is a potent anti‐androgen for the treatment of spontaneous canine BPH, without any negative influence on the function of the testes and the pituitary LH cells. Expand
Determination of concentrations of sex steroids in blood plasma and semen of male dogs treated with delmadinone acetate or finasteride.
Significantly higher 5 alpha-dihydrotestosterone concentrations and significantly lower concentrations of oestradiol and oestrone were found in prostaticsecretions from azoospermic ejaculates compared with prostatic secretions of normos permic and oligozoospermic spermatozoa. Expand
Comparison of the effects of new specific azasteroid inhibitors of steroid 5α‐reductase on canine hyperplastic prostate: Suppression of prostatic DHT correlated with prostate regression
The study provides the first documentation of a tight negative correlation between prostate regression and the prostatic concentration of DHT across a range of treatment regimens, and probed the obverse of the familiar relation between DHT and prostate growth. Expand
Effects of a new steroidal antiandrogen, TZP‐4238 (17 α‐acetoxy‐6‐chloro‐2‐oxa‐4, 6‐pregnadiene‐3, 20‐dione), on spontaneously developed canine benign prostatic hyperplasia
TZP‐4238 produced a regression in spontaneously developed canine BPH, its effects being more potent than those of CMA, suggesting antiandrogenic mechanisms of the agent. Expand